UNSPSC 51182039: Normethandrone

This classification denotes a therapeutic progestin with the molecular formula C19H28O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 743F1Z557A, chemically known as 19-nortestosterone, 17-methyl- but generally known as normethandrone, which bears US NIH Compound Identifier 10576. European Medicines Agency schedules Normethandrone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14667MIG. As of Q4 2014, NORMETHANDRONE remains the US FDA Preferred Term for this commodity.

Normethandrone bears US NLM identifiers UMLS ID C0650248 and NCI Concept Code C95970. SMILES: OC1(C2(C(C3C(CC2)C2C(=CC(=O)CC2)CC3)CC1)C)C..

UNSPSC 51182039 Normethandrone, a Commodity code, covers synthetic anabolic steroids and related pharmaceutical active ingredients that state and local governments procure primarily through cooperative purchasing agreements for institutional pharmaceutical supply chains. The recent activity under this code shows state and local procurement officers sourcing generic multi-source pharmaceuticals and over-the-counter products via established wholesaler networks, with vendors supplying manufacturers' products bearing specific National Drug Codes (NDCs) and meeting current Good Manufacturing Practices (cGMP) and Drug Supply Chain Security Act (DSCSA) compliance. Issuing bodies include state procurement offices administering multistate cooperative purchasing alliances alongside participating county and local government health facilities; these entities typically delegate direct purchasing to authorized wholesalers rather than negotiating individual item-level contracts.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic pharmaceuticals and OTC products across member state and local facilities, including Oregon. Vendors must maintain contractual relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), certify cGMP and DSCSA compliance, carry comprehensive insurance coverage including commercial general liability of $5,000,000 per occurrence, and submit pricing through flat-price, net-price, or WAC-minus formats. The contract term runs two years for new responders with optional extensions, with incumbent vendors' amendments aligned through June 30, 2028. Evaluation weights 75 percent on price competitiveness, 10 percent on fixed pricing for the contract term, and 5 percent each on administrative data format compliance, EDI capability, and acceptance of a 3 percent administrative fee. Award decisions will reflect therapeutic considerations, product availability, patient safety, and member-specific needs; specific budget totals are not disclosed.